Search clinical trials for: MSC2156119J

Total 6 results

Merck KGaA, Darmstadt, Germany

Completed

A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors

Solid Tumors

Japan
Merck KGaA, Darmstadt, Germany

Completed

c-Met Second-Line Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Germany
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available

United States
Chungbuk National University Hospital
Merck KGaA, Darmstadt, Germany

Recruiting

Tepotinib in Solid Tumors Harboring MET Alterations

Solid Tumor | MET Amplification | MET Exon 14 Skipping Mutation

Korea, Republic of
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Colorectal Neoplasms

Spain, United States, France, Italy, Belgium, Czechia, United Kingdom, Russian Federation
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

3

Subscribe